OncoCyte rally propels BioTime, up 60%

|About: BioTime, Inc. (BTX)|By:, SA News Editor

BioTime (BTX +59.9%) jumps on over 9x normal volume in concert with OncoCyte (OCX +221.4%), up on a whopping 1,126x surge in volume after announcing positive results on its lung cancer liquid biopsy test.

BTX owns ~14.7M OCX shares representing a 37.2% stake.

Subscribe for full text news in your inbox